Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

Amicus Makes Steady Progress Toward Achievement of Milestones

CRANBURY, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the third quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.36 per share ($0.29 per share on a non-GAAP basis) for the three months ended September 30, 2008. As of September 30, 2008, cash, cash equivalents, and marketable securities totaled $136.3 million.

"The third quarter of 2008 was another quarter of strong progress for Amicus as we focused on clinical and regulatory execution on our three lysosomal storage disease programs," said John F. Crowley, President and CEO of Amicus Therapeutics. "In recent months, we have continued the process with regulatory authorities in the United States and Europe in order to define the global development plan for Amigal(TM) in Fabry, and we remain on track to provide an update by the end of the year. In our Gaucher and Pompe disease programs, we continue to focus on advancing our ongoing Phase 2 clinical trials with the goal of reporting data in Gaucher in 2009. Finally, our financial position remains strong based on a healthy balance sheet and on the economics from our strategic alliance with Shire, which funds 50% of development costs for our lead programs in addition to success-based clinical and regulatory milestone payments."

Program Advancements

Fabry Disease:

Amigal (migalastat hydrochloride) is an investigational, oral therapeutic being developed for the treatment of Fabry disease. Amicus, along with its partner Shire Human Genetic Ther
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Bill Jacobs Automotive, a group of car dealerships headquartered ... the Heartland Blood Center and offering free oil change coupons ... place Saturday, Jan. 18 at the Bill Jacobs Cadillac and ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill Jacobs ...
(Date:1/15/2014)... JOSE, California , January 15, 2014 ... cancer, today announced the appointment of Thomas C Reynolds MD, ... 20 years, development experience gained in the biotechnology industry, most ... "I am delighted to welcome Tom at this transformative time ...
(Date:1/15/2014)... Two champions of science, technology, engineering, and ... annual competition for middle and high school students designed ... study. The competition presents students with real-world problems experienced ... Mathematics, and Sciences is a program administered by ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... Greg Schlicht and Dax Denman Join as Company ... Algenol Biofuels, developers of,DIRECT TO ETHANOL(TM), the ... continued growth of the company with the,appointments Greg ... General Counsel and Dax Denman as Senior Program ...
... Insmed Inc. (Nasdaq:,INSM) a developer of follow-on biologics ... of Insmed, will present at the,Biosimilars 2008 Conference ... Company,s perspective on the potential impact of follow-on ... a panel on this topic on,Tuesday, September 23, ...
... Study of More Than 60,000 Women Underscores Need for Better ... Implications and Risks Associated with Osteoporosis, MONTREAL, Sept. 15 ... (GLOW) showed that 55 percent of women,diagnosed with osteoporosis do ... their peers. This latest study from GLOW included more than,60,000 ...
Cached Biology Technology:Algenol Biofuels Further Strengthens Team With Key Appointments 2Insmed to Present at Biosimilars 2008 Conference 2Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures 2Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures 3
(Date:4/17/2014)... the University of Texas Medical Branch at Galveston ... treated with radiation for cervical cancer should begin ... , The UTMB researchers, finding a high incidence ... treated with radiation, offer new recommendations that the ... screening about eight years after their initial cervical ...
(Date:4/17/2014)... led by the Australian National University (ANU), have ... and deep-sea temperature variability over the past 5.3 ... understand the climate surrounding ice ages over the ... the relationship between carbon dioxide levels, global temperatures ... University of Southampton (UoS) and the National Oceanography ...
(Date:4/16/2014)... 20-year assessment of Nicaragua,s legal, artisanal green sea turtle ... catch rates of turtles in what may have become ... Wildlife Conservation Society and University of Florida. , During ... 170,000 green turtles were killed between 1991 and 2011, ...
Breaking Biology News(10 mins):Radiation therapy for cervical cancer increases risk for colorectal cancer 2Ancient sea-levels give new clues on ice ages 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 3
... cancer cells that survive chemotherapy leaving the door ... Institute scientists developed an original method for imaging and ... how a chemotherapy drug affects each one. ... and Eran Eden in the lab of Prof. Uri ...
... Munich, Germany and Ann Arbor, MI, USA, Jan 28 ... has joined the Illumina-Connect program, linking them to the ... new tools and applications for Illumina-generated data. , ... Munich, Germany commented: "As the industry,s only provider of ...
... observe in another but have never actually experienced yourself? A ... answer this question. The research, published by Cell Press in ... provides insight into brain mechanisms involved in empathy. Brain-imaging ... feel their own emotions or observe the same emotions in ...
Cached Biology News:Weizmann Institute scientists discover how cancer cells survive a chemotherapy drug 2Genomatix joins Illumina-Connect program 2I feel your pain: Neural mechanisms of empathy 2
... Lauryl Ether 30% concentration ... Preservative. Surfactant. Clear Solution. ... is 1 mL of ... added to 400 mL ...
Mitotic Kinesin-Like Protein 1 (MKLP-1, KNSL5)...
... Contact Printing Kit contains choice of Printing Surface (3 ... over Ti adhesion layer, 1 silicon wafer coated with ... 3 plain glass slides) and PDMS Stamps (3 PDMS ... squares or 100 um x 10 mm or 200 ...
Mouse VEGF R1/Flt-1 Phycoerythrin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Biology Products: